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sorLA is a sorting receptor for amyloid precursor protein (APP) genetically linked to Alzheimer’s disease (AD). Retromer, an adaptor
complex in the endosome-to-Golgi retrieval pathway, hasbeen implicated inAPP transport because retromerdeficiency leads to aberrant
APP sorting and processing and levels of retromer proteins are altered in AD. Here we report that sorLA and retromer functionally
interact in neurons to control trafficking and amyloidogenic processing of APP. We have identified a sequence (FANSHY) in the cyto-
plasmic domain of sorLA that is recognized by theVPS26 subunit of the retromer complex. Accordingly, we characterized the interaction
between the retromer complex and sorLA and determined the role of retromer on sorLA-dependent sorting and processing of APP.
Mutations in the VPS26 binding site resulted in receptor redistribution to the endosomal network, similar to the situation seen in cells
withVPS26knockdown.The sorLAmutant retainedAPP-binding activity but, as opposed to thewild-type receptor,misdirectedAPP into
a distinct non-Golgi compartment, resulting in increased amyloid processing. In conclusion, our data provide a molecular link between
reduced retromer expression and increased amyloidogenesis as seen in patients with sporadic AD.
Introduction
Elevated production of the amyloid  (A) peptide is widely
accepted as a neurotoxic event in Alzheimer’s disease (AD)
(Haass and Selkoe, 2007). A is generated by sequential enzy-
matic cleavages of amyloid precursor protein (APP) by - and
-secretases. In an alternative non-amyloidogenic pathway, APP
is processed by the -secretase enzyme that clips within the A
peptide, thereby precluding amyloid formation. Increasing evi-
dence suggests that intracellular APP trafficking determines the
access of APP to the respective secretases and thereby regulates
the balance between amyloidogenic and non-amyloidogenic pro-
cessing (Sannerud and Annaert, 2009). Thus, dissecting the APP
trafficking pathway is of critical importance for understanding
how A is formed.
sorLA (alternatively named LR11 or SORL1) is a 250 kDa
member of the VPS10p-domain receptor family of type-1 sorting
receptors (Willnow et al., 2008). We and others have shown that
sorLA binds APP and retains it in the Golgi compartment,
thereby preventing processing of the precursor into A (Ander-
sen et al., 2005, 2006; Offe et al., 2006; Schmidt et al., 2007;
Dodson et al., 2008; Rohe et al., 2008). Accordingly, single nucle-
otide polymorphisms in SORL1, the gene encoding sorLA, are
associatedwith late-onset AD, and sorLA expression is reduced in
vulnerable brain regions of AD patients (Scherzer et al., 2004;
Andersen et al., 2005; Dodson et al., 2006; Rogaeva et al., 2007).
Although the significance of sorLA for controlling APP trans-
port and processing is well appreciated, little is known about the
molecularmechanisms that guide the receptor through the intra-
cellular compartments. Trafficking of sorLA is likely to be regu-
lated by a complex system of cytoplasmic adaptor proteins that
bind to specific target sequences within the cytoplasmic tail of the
receptor. This assumption is supported by the observation that
VPS10p, the yeast homolog of sorLA, requires the retromer com-
plex for proper sorting (Seaman et al., 1997, 1998). In mammals,
retromer is composed of at least five different proteins arranged
in two subcomplexes comprising VPS26, VPS29, and VPS35 (the
VPS trimer) and a dimer of two sorting nexin proteins (SNX1 or
SNX2 with SNX5 or SNX6) (Seaman, 2005; Wassmer et al.,
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2007). The cargo binding activity of retromer is assigned to the
VPS trimer, and, in all cases in which this has been studied, bind-
ing is mediated by the VPS35 subunit (Collins, 2008).
The retromer complex is essential for normal cellular func-
tion, as illustrated by the embryonic lethality of knock-out mice
devoid in VPS26 or in SNX1 and SNX2 expression (Lee et al.,
1992; Schwarz et al., 2002). Previous studies have also suggested
that retromer is engaged in binding and trafficking of the mam-
malian sorLA protein (Lane et al., 2010) because knockdown of
either VPS35 or SNX1 results in reduced sorLA expression
(Nielsen et al., 2007).
Similarly to sorLA, expression of the retromer component
VPS35 is decreased in vulnerable regions of AD brains, but the
mechanism by which retromer influences onset of disease re-
mains poorly understood (Small et al., 2005). However, recent
studies reported that retromer deficiency in mice and flies in-
creases the production of A (Muhammad et al., 2008), likely by
impact on APP sorting (Vieira et al., 2010). Because the retromer
complex does not interact directly with APP, we speculated that
sorLA is the molecular link between retromer function and APP
processing. We provide evidence for a direct link between sorLA
and retromer and suggest a model on how they jointly prevent
APP from entering the amyloidogenic pathway.
Materials andMethods
Antibodies.Antibodies used against the following antigens are listed with
their source followed by the dilution factor for Western blot (WB) or
immunofluorescence (IF) applications. Actin (Sigma;WB, 1:1000), APP
C-terminal (O.M.A.; WB, 1:1000; IF, 1:300), APP/8E5 (B. T. Hyman,
Massachusetts General Hospital, Cambridge, MA; IF, 1:300), sol–sorLA
from rabbit, goat, or mouse (C. M. Petersen, Aarhus University, Aarhus,
Denmark; WB, 1:1000; IF, 1:300), CD8 (Santa Cruz Biotechnology; WB,
1:200; M.S.; IF, 1:200), 1-adaptin: (a gift fromM. S. Robinson, Univer-
sity of Cambridge, Cambridge, UK; WB, 1:1000), Mannosidase II (Ma-
nII) (Millipore Bioscience Research Reagents; IF, 1:300), sAPP/WO2
(R. Cappai, The University of Melbourne, Melbourne, Australia; WB,
1:2000), TGN46 (M.S.; IF, 1:300), VPS26 (M.S.; IF, 1:300), VPS35 (M.S.;
IF, 1:300), Snx1 (M.S.; IF, 1:300), and TGN38 (M.S.; IF, 1:300). As sec-
ondary antibodies, we used Alexa Fluor donkey anti-rabbit 488, 546, 555,
or 568, Alexa Fluor donkey anti-mouse 488, and Alexa Fluor donkey
anti-goat 568 or 546 (all from Calbiochem/Invitrogen; IF, 1:300).
DNA constructs and recombinant proteins. The construct encoding the
full-length sorLA–FANSHY36A mutant was generated by site-directed
mutagenesis of the human sorLA cDNA in pcDNA3.1zeo() vector us-
ing primers 5-GCA GCT TCA CCG CCG CTG CCG CAG CGG CAG
CTA GCT CCA GGC-3 and 5-GGC AAC TAG AAG GCA CAG TCG
AGG-3, and, accordingly, 5-GCC TGGAGC TAGCTGCCGCTGCGG
CAG CGG CGG TGA AGC TGC-3 and 5-CTT GCA AAC GTC ACT
GCT GCC TCC-3. The wild-type (WT) sorLA fragment was replaced by
the mutated PCR fragment via SfuI and XhoI. The CD8ED–sor-
LACD–WT construct was made as described previously (Seaman, 2004),
involving PCR amplification of the cytoplasmic tail of WT sorLA and
adding an AflII site to form an in-frame fusion with humanCD8. Thus,
the cytoplasmic domain of sorLA was joined to the lumenal domain of
CD8. Site-directed mutagenesis of the sorLA tail was accomplished
using theQuikChange kit by Stratagene, following the instructions of the
manufacturer.
H6Ubi-tail proteins were produced in Escherichia coli BL21/DE3 pL-
ysS as described previously (Andersen et al., 2000). Expression constructs
were prepared using the following forward and reverse primers: 5-GGC
GGA TCC ATC GAG GGT AGG TAC ACG AAG CAC CGG AGG CTG
CAG AGC AGC-3 and 5-CGG TTC GAA TTC AGG CTA TCA CCA
TGGGGACGTCATCTG-3. Bacterial cells were lysed and applied to an
Ni2-charged NTA column equilibrated with 50 mM Tris-HCl, pH 8.0,
and 500 mM NaCl. Bound protein was eluted by addition of 20 mM EDTA.
The quality of the H6Ubi-tail proteins was tested by SDS-PAGE analysis.
The human VPS26A protein (GenBank accession number
NP_004887) was expressed with a C-terminal histidine tag by using the
pET11a vector (Novagen) and purified from E. coli lysate on Talon beads
(Invitrogen). The GGA1–VHS domain was produced as described pre-
viously (Cramer et al., 2010).
A vector for short-hairpin RNA (shRNA) knockdown of VPS26 was
prepared based on the siRNA sequence against VPS26 (AAU GAU GGG
GAA ACC AGG AAA), the BLOCK-iT Inducible H1 RNAi Entry Vector
kit (Invitrogen), and a pair of oligonucleotides. The oligos used were as
follows: 5-CACC AAT GAT GGG GAA ACC AGG AAA GAGA TTT
CCTGGT TTCCCCATCATT-3 (top strand) and 5-AAAA AATGAT
GGG GAA ACC AGG AAA TCTC TTT CCT GGT TTC CCC ATC
ATT-3 (bottom strand).
APP metabolism. SH-SY5Y cells were cultured in DMEM F-12 (Invit-
rogen) supplemented with 10% FBS and 5% penicillin/streptomycin. To
obtain stable cell lines, SH-SY5Y cells were transfected using HiFect
(Amaxa) with constructs encoding sorLA–WTor sorLA–FANSHY36A.
Transfected cells were selected by adding 300 g/ml zeocin (Invitrogen)
to themedium48h after transfection.Determination ofAPPmetabolism
was performed using the endogenous level of APP expression in the
stable transfected SH-SY5Y cells. A total of 5 106 cells were cultured in
T25 flasks (Nunc) and allowed to grow to90% confluency before shift-
ing themedium to serum-freeDMEMF-12. Bothmedium and cells were
harvested after another 45 h. Cells were lysed using 10 mM Tris-HCl, pH
8, 5 mM EDTA, 1% Triton X-100, and 1% NP-40. Equal amounts of
protein from cells and medium were suspended in SDS loading buffer
and loaded onto 4–16% SDS-PAGE, followed byWB. The nitrocellulose
membranes (GE Healthcare) were probed for sorLA, holo-APP, and ac-
tin. The A1–40 level was determined by ELISA (Invitrogen).
Cell surface biotinylation. SH-SY5Y cell lines stably expressing either
sorLA–WT or sorLA–FANSHY36A were grown in six-well plates and
used at 80% confluency. Cells were washed twice with ice-cold PBS and
incubated for 30 min on ice with PBS containing 1 mg/ml EZ-linked
sulfo-NHS-S-biotin (Pierce). Biotinylation was quenched by 20 min of
incubation with 100 mM glycine. The quenching buffer was removed by
washing in PBS, and the cells were lysed in lysis buffer (PBS, 1% Triton
X-100, and 0.1% SDS) supplemented with Complete proteinase inhibi-
tor (Roche). To precipitate the biotinylated proteins, cell lysates were
incubated with streptavidin beads (GE Healthcare) overnight at 4°C.
After incubation, the beads were washed three times in PBS before
being eluted with 50 l of SDS sample buffer and incubated at 98°C
for 5 min. The total protein fraction (20 g of sorLA–WT or sorLA–
FANSHY36A) and the cell surface fraction (20 l of sorLA–WT and
sorLA–FANSHY36A)were loaded onto SDS-PAGE (4–16%), followed by
WB. Themembrane was probed with antiserum against sol–sorLA.
Protein lifetime and maturation. A pulse-chase experiment was per-
formed using 1.5 106 of SH-SY5Y cells stably expressing sorLA–WTor
sorLA–FANSHY36A. The cells were incubated in cysteine and
methione-free medium (Sigma) for 15 min before metabolic labeling
[200Ci/ml L-[ 35S]cysteine and L-[ 35S]methione (Pro-mix; GEHealth-
care) in the presence of 1 Glutamax (Sigma)] for 40 min. Thereafter,
the cells were washed in PBS and incubated in complete DMEM and
chased for the indicated times, followed by cell lysis. sorLA–WT and
sorLA–FANSHY36A were immunoprecipitated using Gamma-bind
Sepharose beads (GE Healthcare) coated with rabbit serum against sol–
sorLA. The precipitated proteins were analyzed by SDS-PAGE, followed
by autoradiography.
As described previously (Seaman, 2007), determination of the
CD8ED–sorLACD–WT and mutant stability was performed in the pres-
ence of cycloheximide, except that the cells were grown in 90 mm tissue
culture dishes and were treated with cycloheximide for 4 h.
Confocal microscopy. With the purpose of studying colocalization of
sorLA with different marker proteins, we used primary hippocampal
neuronal cultures and human SH-SY5Y cell lines stably expressing either
sorLA–WT or sorLA–FANSHY36A. Furthermore, we used SH-SY5Y
cells transiently transfected with either CD8ED–sorLACD–WT or
CD8ED–sorLACD–FANSHY36A in combination with sorLA–WT,
sorLA–FANSHY36A, sorLA–F123A, sorLA–FTAF34A, and sorLA–
Y173F. The following procedure was used in connection with all cell
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staining experiments unless otherwise stated. The cells were fixed in 4%
paraformaldehyde for 10 min, after which the paraformaldehyde was
removed by washing three times in PBS. The cells were then permeabil-
ized for 30 min by incubation in PBS containing 0.1% Triton X-100.
Next, cells were blocked for 30 min in blocking buffer [PBS containing
10% fetal calf serum (FCS)]. After blocking, the cells were incubatedwith
primary antibodies diluted in blocking buffer for 2 h at room tempera-
ture or overnight at 4°C. The cells were then washed three times in PBS
and incubated with secondary antibodies for 2 h at room temperature in
the dark. The cells were imaged using a Carl Zeiss confocal LSM 510
META laser microscope with 40, NA 1.2 C-Apochromat objectives
(Carl Zeiss).
Endosome-to-Golgi retrieval of CD8ED–sorLACD–WT and CD8 ED–
sorLACD–FTAF34A was investigated using the antibody-uptake assay
as described previously (Seaman, 2004, 2007). In this assay, cells express-
ing the CD8-reporter construct of interest were incubatedwith anti-CD8
antibody continuously for 3 h. After fixation, the cells were permeabil-
ized and labeledwith anti-TGN46 antisera and then fluorescently labeled
with anti-mouse and anti-rabbit secondary antibodies. The cells were
imaged as described previously (Seaman, 2007).
Live-cell imaging. PC12 cells were maintained in DMEM (4.5 mg/L glu-
cose) supplementedwith 10%horse serumand5%fetal bovine serum.Cells
were incubated at 37°Cwith 5%CO2. The plasmid containingmCherry and
GFP-tagged APP or sorLA were transfected into 70–80% confluent PC12
cells using Lipofectamine 2000 (Invitrogen). The day after transfection, the
cells were seeded onto coverslips coated with Matrigel (BD Biosci-
ences). The cellswere incubated in serum-freemediumsupplementedwith
NGF (50 ng/ml) 24–48 h before investigation. The cells were investigated
using a Nikon E800 epifluorescence microscope, and images were captured
using a CCD camera. Movies were generated by obtaining images at 1
frame/s with a 100 oil-immersion objective (NA 1.4). The vesicle move-
ment was analyzed by generation of kymostacks using a homemade NIH
ImageJ KymoToolbox plugin (http://rsb.info.nih.gov/ij/; available on re-
quest at Fabrice.Cordelieres@curie.fr). A number of vesicles was analyzed
per condition (APP, 354 vesicles; sorLA–WT, 226 vesicles; sorLA–
FANSHY36A, 287 vesicles) over three experiments (n 3).
Fluorescence lifetime imaging microscopy (FLIM) was conducted to
determine FRET between APP and either sorLA–WT or the sorLA–
FANSHY36A mutant. The FLIM experiments of the cells were investi-
gated on a Carl Zeiss confocal LSM 510 META laser microscope with a
40, NA 1.2 C-Apochromat objective. Thismicroscope is equippedwith
a mode-locked titanium–sapphire two-photon laser (Mai-Tai; Spectra
Physics), photon counting card (SPC830), and associated software from
Becker & Hickl (SPCM program). APP was detected with antibody 8E5
and anti-rabbit labeled with Alexa Fluor 488. Alexa Fluor 488 fluores-
cence was detected with a PMC-100 detector (Hamamatsu) after two-
photon excitation at 800 nm. Images in the SPCM program were 256
256 pixels in size and 256 time channels in depth, and they were acquired
with the following settings in the LSM program: pixel dwell time, 1.6 s;
line average, 1 and 0.11 m/pixel (zoom 4).
Fluorescence lifetime decay curves were collected in 10 cycles of 10 s.
Lifetimes were measured for APP labeled with Alexa Fluor 488 in the
presence and absence of sorLA–WT or sorLA–FANSHY36A labeled
with Alexa Fluor 543, respectively. Lifetime curves were obtained from
10–15 cells. The fluorescence decay curves were fitted to a monoexpo-
nential decay function in SPCImage (Becker &Hickl, version 2.9.4.1993)
with bin set to 1 (3  3 pixels) and amplitude threshold set to 25. The
scatter parameter was fixed to 0, and all other parameters were left free.
As instrument response function, we used the one automatically calcu-
lated by SPCImage.
Proximity ligation assay. According to protocol (So¨derberg et al.,
2006), the localization and interactions between endogenous APP and
sorLA–WT or the sorLA–FANSHY36A mutant were analyzed using a
proximity ligation assay (PLA). SH-SY5Y cells transfected with
sorLA–WT or sorLA–FANSHY36A were fixed on coverslips with 4%
paraformaldehyde, andmembranes were permeabilized with 0.5% sapo-
nin. The cells were incubated overnight at 4°C with mouse anti-sorLA
(20C11) and rabbit anti-APP (C terminal). After washing three times, the
cells were incubated with secondary antibodies conjugated with oligonu-
cleotides: PLUS-anti-rabbit PLA probe and MINUS-anti-mouse PLA
probe, respectively. In the following steps, the PLUS and the MINUS
probes in close proximity (40 nm) were hybridized and ligated. The
interacting probes were then amplified with polymerase. DNA strands
were visualized by hybridization of fluorescently labeled oligonucleotides
and analyzed by fluorescencemicroscopy (563 nm). All incubations were
done at 37°C using the incubation times and buffers given by the manu-
facturer (Olink Bioscience).
CD8 native immunoprecipitations (IPs) were performed as described
previously (Seaman, 2007). Cells were grown in 140mmdishes and lysed
in 1 ml of lysis buffer (0.1 M Mes-NaOH, pH 6.5, 1 mM Mg-acetate, 0.5
mM EGTA, 200MNa-vanadate, 1% digitonin, and protease inhibitors).
The cell lysate was centrifuged for 5 min at 10,000  g, after which the
supernatant was cleared by incubationwith 50l of protein-A Sepharose
(25%) for 30 min at 4°C. The lysates were then centrifuged again for 5
min at 10,000 g and, subsequently, transferred to a fresh tube contain-
ing5 g of anti-CD8 prebound to protein-A Sepharose. After 90 min
of incubation at 4°C, the IPs were washed four times with lysis buffer.
Next, the sampleswere desiccated in a Speed-Vac, resuspended into 50l
of SDS-PAGE loading buffer, and subjected to SDS-PAGE and WB
analysis.
Large-scale anti-CD8 native IPs were performed as above using six 140
mm dishes of cells for each CD8 reporter. After washing, the IPs were
combined into a spin column (one column per CD8 reporter), and the
bound proteins were eluted using 2 150l aliquots of 200mM glycine-
HCl, pH 2.3. After elution, the proteins were precipitated by addition of
1.2 ml of ice-cold acetone. After precipitation with acetone, the precipi-
tated proteins were dried in a Speed-Vac and then prepared for liquid
chromatography with tandem mass spectrometry analysis as described
previously (Harbour et al., 2010).
Peptide pull-downs and mass spectrometry. Peptides containing the cy-
tosolic tail of human sorLA were purchased from Eurogentec and dis-
solved in ultra-pure water (1 mg of peptide in 200 l of H2O). Peptide 1
was soaked in 4l of DMSO before dissolving in water. According to the
SulfoLinkmanual (Pierce), the peptideswere then coupled to iodoacetyl-
activated agarose (SulfoLink Coupling Resin; Pierce). As a control for
unspecific resin binding, one batch of beads was treated in parallel but
without addition of the peptide. The binding efficiency was estimated by
applying a BCA assay on the peptide solution before and after coupling to
the Sepharose. A90% decrease in signal (and a decrease of peptide in
solution therewith) was considered as efficient coupling. After the cou-
pling, free binding sites were blocked by 50 mM cysteine.
Animals were killed, and kidneys were removed rapidly, rinsed briefly
in PBS, and homogenized with an Ultra-Turrax (IKA) in 1ml of ice-cold
RIPA buffer (0.2% SDS, 0.1% sodium deoxycholate, 1%NP-40, 150 mM
NaCl, 50 mM Tris-HCl, 2 mM 2-mercaptoethanol, and 5 mM EDTA, pH
7.4) or DOC buffer (10% sodium deoxycholate and 500 mM Tris-HCl,
pH 7.4) per 50 mg of tissue. The homogenates were incubated on ice for
10 min before they were sonicated. To enrich cytosolic proteins, the
lysate was cleared by centrifugation at 126.200  g for 30 min at 4°C.
Protein concentrations were estimated by performing a BCA assay (with
comparison with a BSA standard). One milligram of protein was incu-
bated overnight at 4°C with 50 l of settled peptide-coupled resin. Next,
the column was washed five times for 5 min with 1 ml of either RIPA or
DOCbuffer. Bound proteins were eluted by incubating the beads in 20l
of 4 SDS-PAGE sample buffer (200 mM Tris-HCl, 8% SDS, 0.04%
bromophenol blue or orange G, 40% glycerol, and 200 mM
2-mercaptoethanol, and pH 6.8) at 95°C for 5 min. The samples were
subjected to SDS-PAGE and stained with Coomassie blue G250 (Sigma-
Aldrich). The bands of interest were excised, and the gel pieces were
stored at 4°C in 1% acetic acid. Mass spectrometry (MS) for protein/
peptide identification was performed by Gunnar Dittmar (Max Del-
brueck Center, Berlin, Germany), Heike Stephanowitz (Leibniz Institute
for Molecular Pharmacology, Berlin, Germany), or Bent Honore´ (Aar-
hus, Denmark).
Surface plasmon resonance analysis.As described previously (Andersen
et al., 2006), immobilization of H6Ubi–sorLA–WT and H6Ubi–sorLA–
FANSHY36A was performed after dialysis against sodium acetate, pH
4.0 and coupled to CM5 chips (BIAcore). The sample and running buffer
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used for binding analysis were 10 mM HEPES, pH 7.4, 150 mM NaCl, 3
mM EGTA, and 0.005% Tween 20. The regeneration of the chip was
performed by alternating 10 l pulses of regeneration buffer (10 mM
glycine hydrochloride, pH 4.0, 20 mM EDTA, 500 mMNaCl, and 0.005%
Tween 20) and 0.01% SDS. All measurements were conducted on a BIA-
core3000 instrument.
Immunoelectron microscopy. For electron microscopy, cells were fixed
with 2% formaldehyde and 0.1% glutaraldehyde in 0.01 M PBS, pH 7.4,
for 10 min at room temperature. The cells were washed three times and
removed with a rubber policeman in the same buffer containing 1%
gelatin (Merck). The cells were then pelleted and embedded in 12%
gelatin, infiltrated with 2.3 M sucrose in PBS for 30 min, and, finally,
frozen in liquid nitrogen. Ultrathin cryosections (70  90 nm) were
obtained with an FCS Reichert Ultracut S cryo-ultramicrotome at
	100°C and collected on 200 mesh nickel grids. The sections were incu-
bated overnight with a polyclonal rabbit anti-sol–sorLA antibody at
1:1000 before 2 h of incubation with goat anti-rabbit gold (10 nm) (Bio-
Cell). All incubations were performed at 4°C. Finally, the sections were
contrasted with methyl cellulose containing 0.3% uranylacetate and
studied in a Philips CM100 electron microscope.
Results
Retromer binds and regulates the localization of sorLA
Expression of sorLA and retromer has been detected previously
in a subset of neuronal cells within the mammalian brain. To
determine whether these proteins colocalize, we performed im-
munostaining for sorLA and the retromer proteins VPS35 and
SNX1 in primary hippocampal cultures. We observe that sorLA
and the two retromer proteins partly overlap in a perinuclear
compartment (Fig. 1A). Noticeably, not all cells stained for
sorLA, which is in line with the previously shown heterogeneous
cellular pattern of sorLA immunostaining of brain, including
hippocampus (Motoi et al., 1999).
Based on the colocalization seen in hippocampal neurons, we
decided to investigate whether the retromer complex regulates
the intracellular distribution of sorLA. For that purpose, we pre-
pared a shRNA knockdown vector against the human VPS26
protein and transfected the construct into SH-SY5Y cells to test
for its ability to reduce VPS26 expression. As seen byWB, VPS26
and VPS35 protein expression were clearly visible in nontrans-
fected cells.However, VPS26was undetectable in cells transfected
with the shRNA vector (Fig. 1B). We also found that the level of
VPS35was decreased inVPS26-depleted cells. This observation is
in agreement with previous studies showing that VPS proteins of
the cargo-selective subcomplex stabilize each other (Arighi et al.,
2004; Seaman, 2004) (Fig. 1B).
We next performed confocal fluorescence microscopy to in-
vestigate whether retromer deficiency changes the subcellular lo-
Figure 1. Retromer physically interacts with sorLA. A, Immunostaining of primary hippocampal neurons for sorLA (red) and VPS35 (in green; top) or SNX1 (in green; bottom). B, WB analysis of
lysates fromSH-SY5Y cells after transfectionwith () orwithout (	) an shRNAvector against humanVPS26. Actin is used as loading control.C, SH-SY5Y cellswere transfectedwith sorLA–WT (top)
or sorLA–WTtogetherwith theVPS26 shRNAknockdownvector (bottom) sorLA (red) and theGolgimarkerManII (green).D, Co-IP analysis of CD8 chimeric proteins aspreviously (reportedbySkinner
and Seaman, 2009). Precipitated proteins were analyzed by WB.
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calization of sorLA. SH-SY5Y cells were transfected with an
expression vector for sorLA alone or cotransfected with the
VPS26 shRNA knockdown vector. In the presence of functional
retromer in single-transfected SH-SY5Y cells, sorLA was ob-
served within the perinuclear region showing strong overlap with
the Golgi marker ManII. However, in the retromer knockdown
cells (i.e., double-transfected cells), the receptor displayed amore
punctate and peripheral distribution (Fig. 1C). This change in
sorLA localization suggests that retromer acts in the retrieval of
sorLA from a peripheral compartment (e.g., early and/or recy-
cling endosomes) to the Golgi.
Because knockdown of VPS26 alters sorLA distribution, we
wanted to examine whether sorLA and retromer can physically
interact. We therefore performed co-IP experiments using a
chimeric reporter construct encoding the extracellular do-
main (ED) of CD8 fused to the cytoplasmic domain (CD) of
sorLA (CD8ED–sorLACD–WT). Because
previous reports described that the retro-
mer complex associates with the cytoplas-
mic tail of the cation-independentmannose
6-phosphate receptor (CIMPR), we used a
CD8ED–CIMPRCD–WT fusion construct
as a positive control. As negative control, we
applied CD8 alone or a mutated variant
(CD8ED–CIMPRCD–WLM33A) lacking
the retromer binding site (Seaman,
2007). IP experiments were performed on
lysates from transfected HeLa cells using an
anti-CD8 antibody. As shown in Figure 1D,
the retromerproteinsVPS35andVPS26co-
precipitated with CD8ED–sorLACD–WT
and CD8ED–CIMPRCD–WT but not with
CD8ED–CIMPRCD–WLM33A or CD8
alone. These data provide evidence that ret-
romer and sorLAphysically associatewithin
cells (Fig. 1D).
Identification of the retromer binding
motif in sorLA
To identify the retromer binding site in
sorLA, we prepared overlapping 15-mer
peptides corresponding to the cytoplas-
mic tail (sorLA peptides 1–5; Fig. 2A) and
coupled these peptides to Sepharose resin.
The peptides were then incubated with
homogenates of mouse kidney—a tissue
shown to contain high levels of retromer
and sorLA (Reiche et al., 2010 and data
not shown)—and bound proteins were
eluted and analyzed by SDS-PAGE, fol-
lowed by Coomassie staining. Prominent
bands were subsequently identified by
MS. Interestingly, we noticed that peptide
5 covering the sequence closest to the
transmembrane domain of sorLA bound
several proteins, including VPS26 (Fig.
2B). Notably, peptide 5 is rich in aromatic
residues, including the di-phenylalanine
motif FTAF (Fig. 2A). This sequence is
similar to the FYVF motif in the yeast
VPS10p receptor that is believed to medi-
ate binding to the yeast retromer complex
(for review, see Seaman, 2008).
To test whether the aromatic residues present in peptide 5
are involved in retromer binding, we mutated the FTAF motif
within the CD8ED–sorLACD–WT to a tetra-alanine sequence
(CD8ED–sorLACD–FTAF34A). We then repeated the co-IP
experiment in HeLa cells, comparing retromer precipitation
for CD8ED–sorLACD–WT and CDED–sorLACD–FTAF34A
(Fig. 2C). We found that both VPS26 and VPS35 associated
with the chimeric protein carrying theWT sorLA tail sequence
(Fig. 2C). However, when the cytoplasmic FTAF motif was
mutated, the interaction with retromer was abolished (Fig.
2C). Additionally, 1-adaptin, a component of the clathrin
AP-1 complex, showed specific interaction with CD8ED–
CIMPRCD–WT but did not bind to sorLA. Notably, neither
the tail of APP nor of the -site APP-cleaving enzyme (BACE)
could precipitate components of the retromer in this assay
(Fig. 2C).
Figure 2. Aromatic residues in sorLA are important for the association with retromer proteins. A, Amino acid sequences of
humanWT andmutant sorLA cytoplasmic tails. Overlapping 15-mer peptides used for pull-down studies are indicated. B, Precip-
itated proteins are visualized by SDS-PAGE and Coomassie staining. The arrowhead marks the VPS26 subunit identified by MS in
several independent experiments.C, Co-IP analysis of CD8 chimeric proteins fromtransfectedHeLa cells. Precipitatedproteinswere
analyzed byWB. The asterisk in lane CD8 ED–APP CD–WT indicates an unknown protein unrelated to VPS26.D, Co-IP of VPS35with
sorLA–WT from stably transfected SH-SY5Y cells. E, F, Surface plasmon resonance analysis using 50 nM VPS26 protein or 500 nM
GGA1–VHS domain applied to biosensor surfaces immobilized with sorLA–WT and sorLA–FANSHY36A tails fused to H6Ubi.
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Phenylalanine residue 12 (F12; numbering according to the
tail sequence in Fig. 2A) is also part of an FXNPXY-like motif
known to function in the clathrin-dependent endocytosis path-
way [i.e., for the low-density lipoprotein receptor (Davis et al.,
1986)]. Therefore, we prepared a sorLA mutant wherein the
FANSHY hexa-peptide was substituted with six alanine residues.
SH-SY5Y cells were transfected with either sorLA–WT or sorLA–
FANSHY36A constructs, and co-IP of the retromer was per-
formed. Because co-IP of VPS35 was only seen for cells that
expressed sorLA–WT (Fig. 2D), we conclude that aromatic resi-
dues in sorLA are essential for binding the retromer complex.
To further investigate the binding partners of the cytoplasmic
domain of sorLA, we applied a large-scale IP assay using HeLa
cells stably transfected with the CD8ED–CIMPRCD–WT,
CD8ED–sorLACD–WT, and CD8ED–sorLACD–FANSHY36A
mutant reporter constructs, respectively. Proteins immunopre-
cipitated with anti-CD8 antibodies were subsequently analyzed
by MS. As shown in Table 1, peptides from the clathrin adaptor
AP-1 (adaptins) were detected in the CD8ED–CIMPRCD–WT
sample, along with peptides from the retromer protein VPS35.
The CD8ED–sorLACD–WT sample contained peptides from
VPS35, VPS26, andVPS29, but only one peptide fromVPS35was
detected in the CD8ED–sorLACD–FANSHY36A sample. Similar
numbers of peptides from the CD8 protein, GAPDH, and elon-
gation factor were present in all three samples, indicating that
comparable amounts ofmaterial were analyzed fromeach sample
(Table 1). Next, we measured whether recombinant VPS26 can
interact directlywith the 54 aa tail of sorLAusing surface plasmon
resonance analysis. Whereas the nonmutated cytoplasmic part of
sorLA bound strongly to VPS26, the tail of sorLA–FANSHY36A
failed to do so (Fig. 2E). However, both proteins bound to the
GGA1 VHS domain shown previously to interact in a region that
shares no overlap with the FANSHY motif (Nielsen et al., 2001;
Cramer et al., 2010) showing a specific disruption of the VPS26
binding site (Fig. 2F).
Together, these data demonstrated that sorLA binds the
VPS26 subunit of retromer and suggest that this interaction re-
quires aromatic residues in the receptor tail.
Lack of retromer binding alters the localization of
sorLA–FANSHY3As
We next investigated the effect of mutating the FANSHY se-
quence on cellular distribution of sorLA. In this assay, SH-SY5Y
cells were double transfected with different combinations of
CD8-reporter and full-length sorLA constructs to analyze the
localization pattern of both proteins within the same cell. First,
we transfected SH-SY5Y cells with the CD8ED–sorLACD–WT
construct in combination with sorLA–WT (Fig. 3A). The cells
were subsequently stained with antibodies against the ED of
sorLA and the CD8 reporter. As expected, we found a strong
colocalization between CD8ED–sorLACD–WT and sorLA–WT in
a perinuclear Golgi-like compartment, demonstrating that the
CD8 tag did not influence the subcellular distribution. Likewise,
we found that CD8ED–sorLACD–FANSHY36A and sorLA–
FANSHY36A robustly overlapped albeit in a more peripherally
localized compartment (Fig. 3A). Notably, when combining the
mutant sorLA–FANSHY36A with CD8ED–sorLACD–WT, we
observed only minor colocalization. Rather, the majority of
sorLA–FANSHY36A was observed in a peripheral and punctu-
ate expression pattern (Fig. 3B). Transfection with the reverse
constructs, i.e., CD8ED–sorLACD–FANSHY36A and sorLA–
WT, showed a similar dispersed localization of themutant recep-
tor tail. In conclusion, sorLA–FANSHY36A localize differently
from sorLA–WT when transfected into the same cell.
Because our biochemical experiments suggested a critical role
for the sequences F9TAF12 and F12ANSHY that share F12, we
compared the subcellular distribution of CD8ED–sorLACD–WT
with two mutants lacking either F9 and F12 (sorLA–FTAF34A)
or only F12 (sorLA–F123A) (compare with Fig. 2A). In accor-
dance with the in vitro data, substitutions in sorLA–FTAF34A,
but also in sorLA–F123A, shifted the receptor distribution to the
peripheral compartment similar to that observed for the sorLA–
FANSHY36A mutant (Fig. 3C). In comparison, mutating ty-
rosine 17 in FANSHY to a phenylalanine (sorLA-Y173F) did not
influence the perinuclear expression pattern. Collectively, we
therefore conclude that F12 in the receptor tail is important for
retromer to control sorLA sorting.
To establish that the aberrant subcellular distribution of the
mutants was a consequence of deficient retromer binding, we
cotransfected the SH-SY5Y cells with the shRNA construct to
knock down expression of VPS26. In the presence of functional
retromer, CD8ED–sorLACD–WTwas confined to the perinuclear
region, but transfection with the VPS26 shRNA clearly redistrib-
uted the receptor to a more distal and dispersed compartment in
which it colocalized with the sorLA–FANSHY36A mutant (Fig.
3D). These data strongly suggest a functional link between retro-
mer, its binding to the FANSHY sequence, and sorting of sorLA.
Immunoelectronmicroscopy analysis ofWT andmutant
sorLA
To examine the protein localization inmore detail, we performed
immunoelectron microscopy on cells stably transfected with ei-
ther sorLA–WT or sorLA–FANSHY36A constructs. Unfortu-
nately, despite several attempts, we did not succeed in generating
a stable cell line that expressed sorLA–F123A.However, because
the F123A and FANSHY36A mutations had similar cellular
localization patterns as shown in the CD8-reporter experiment
(cf. Fig. 3B), all subsequent studies were performed using the
FANSHY36A mutant line. In agreement with the confocal IF
data, immunoelectron microscopy revealed that sorLA–WT re-
sides partly in Golgi compartments but also in large multivesicu-
lar bodies in the vicinity of the nucleus, whereas only small
amounts of theWT receptor were present in peripheral compart-
ments except for pronounced labeling of the plasma membrane
(Fig. 3E). In contrast, the majority of sorLA–FANSHY36A was
Table 1. MS analysis of anti-CD8 native IP assays from HeLa cell lysates using CD8
reporter proteins
Protein detected CD8 ED–CIMPR CD–WT CD8 ED–sorLA CD–WT
CD8 ED–sorLA CD–
FANSHY36A
1-Adaptin 714 (14) 0 0
-Adaptin 434 (9) 30 (1) 0
1-Adaptin 330 (7) 0 0
GGA2 0 46 (1) 0
VPS35 79 (5) 426 (7) 27 (1)
VPS26A 0 26 (1) 0
VPS29 0 39 (1) 0
SNX2 51 (2) 0 0
SNX6 150 (1) 0 0
Rab7A 36 (1) 22 (1) 26 (1)
CD8 1783 (6) 1425 (5) 188 (4)
GAPDH 444 (6) 93 (4) 407 (4)
EF1A1 579 (6) 394 (5) 353 (5)
TfnR 424 (12) 1982 (13) 184 (8)
Immunoprecipitates of cells stably expressing the indicated CD8-reporter construct using an antibody against CD8.
Values indicate theMascot score and numbers in parentheses the quantity of peptides detected. The data are based
on searching the MaxQuant database.
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observed in small electron-dense vesicles near the plasma mem-
brane but only to a small extent within the Golgi.
Reduced expression of sorLA–FANSHY36A at the cell
surface
The immunoelectron microscopy data also revealed low abun-
dance of sorLA–FANSHY36A at the plasma membrane when
compared with the WT receptor (Fig. 4A). To quantitatively de-
termine surface expression of the sorLA variants, we incubated
the transfected SH-SY5Y cells with a membrane-impermeable
biotin reagent at 4°C. A fraction of the total cell lysates and the
biotinylated protein were resolved by SDS-PAGE analysis, and
sorLA expression was determined by WB (Fig. 4B). Quantifica-
tion of these bands demonstrated 48.3  2.7% less sorLA–
FANSHY36A at the plasma membrane compared with the level
of sorLA–WT.
We then speculated about whether the low cell-surface ex-
pression of sorLA–FANSHY36Amight be a consequence of def-
icits in the secretory pathway, leading to less mature receptor
reaching the cell surface. To test this hypothesis, we examined
receptor maturation using a pulse-chase protocol. The kinetics
of receptor maturation (i.e., the acquisition of glycosylation) was
indistinguishable between sorLA–WT and sorLA–FANSHY36A
as shown by a similar pattern of high and low glycosylated sorLA
(Fig. 4C).
When sorLA reaches the plasma membrane, some receptor
molecules can undergo cleavage by metalloproteases, leading to
secretion of the soluble ED into themedium (Hampe et al., 2000).
The time needed to reach the cell surface can be estimated by
quantification of secreted soluble sorLA from the pulse-chase
experiment. Accordingly, we immunoprecipitated newly synthe-
sized and shed EDs from the cell culture medium at 60, 90, 120,
Figure 3. Mutation of the FANSHY motif changes the cellular localization of sorLA. A, SH-SY5Y cells cotransfected with either CD8 ED–sorLA CD–WT and sorLA–WT (top) or CD8 ED–sorLA CD–
FANSHY36A and sorLA–FANSHY36A (bottom) were stained for the extracellular domains of CD8 (green) or sorLA (red). B, SH-SY5Y cells were transfected with a combination of constructs
encoding either CD8 ED–sorLA CD–WT and sorLA–FANSHY36A (top) or CD8 ED–sorLA CD–FANSHY36A and sorLA–WT (bottom). The circled areas represent the perinuclear region and the more
distal punctuate region (numbered 1 and 2), respectively. C, Merged pictures of cotransfected SH-SY5Y cells with CD8 ED–sorLA CD–WT in combination with sorLA–FTAF34A, sorLA-F 123A, or
sorLA–Y 173 F. Arrowheads indicate receptor localization in region 2.D, SH-SY5Y cellswere transfectedwith sorLA–FANSHY36A and CD8 ED–sorLA CD–WT in either the absence (top) or presence
(bottom) of the shRNA VPS26 knockdown vector. Arrowheads indicate colocalization in non-Golgi (non-perinuclear) compartments. E, Electron microscopy analysis of sorLA–WT and sorLA–
FANSHY36A in the stably expressing SH-SY5Y cell lines. Arrowheads indicate receptor localization inmultivesicular bodies (white), Golgi (orange), and peripheral vesicles (green). Nu, Nucleus; G,
Golgi; MV, multivesicular bodies; PM, plasma membrane.
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Figure 4. Characterization of sorLA transport in SH-SY5Y cell lines. A, Immunoelectron microscopy of sorLA–WT and sorLA–FANSHY36A. Nu, Nucleus. Arrowheads in white
indicate surface labeling andmutant receptors in the vicinity of the plasmamembrane by green arrowheads. B, The level of biotinylated receptors at the cell surface (Figure legend continues.)
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and 240 min after protein labeling. Neither the sorLA–WT nor
sorLA–FANSHY36A EDs were secreted after 60 min chase, but
EDs from both proteins were secreted to a similar extent at later
time points, i.e., 120 and 240 min (Fig. 4D). Together, these
experiments suggest that anterograde transport of newly synthe-
sized sorLA to the cell surface was not affected bymutation of the
FANSHY motif in the cytoplasmic tail.
sorLA–FANSHY36Amutant fails to enter the endosomal
sorting pathway
We next investigated whether enhanced endocytic uptake and
delivery to lysosomes for degradation might account for the im-
paired surface exposure of the sorLA–FANSHY36Amutant. Ac-
cordingly, we metabolically labeled SH-SY5Y cells expressing
either sorLA–WT or sorLA–FANSHY36A for 40 min and
chased proteins for the following 48 h. However, we failed to
detect any major difference in turnover between the WT and
mutant receptor (Fig. 4E). These data suggest that the mutant
does not exhibit increased lysosomal targeting and degradation
in SH-SY5Y cells (Fig. 4E).
The predominant expression of sorLA–FANSHY36A in
small electron-dense vesicles near the plasmamembrane led us to
suggest that themutant might be impaired in retrograde traffick-
ing from tubular endosomal network (TEN) and back to the
Golgi, a pathway that is critically dependent on the retromer
complex.
First, we studied colocalization of sorLA–WT and sorLA–
FANSHY36A with the Golgi markers ManII and TGN46 (Fig.
4F). Remarkably, we found only a modest overlap between
sorLA–FANSHY36A and ManII and TGN46, whereas sor-
LA–WT showed a much more pronounced colocalization (Fig.
4F) in line with the speculated defect in retrograde transport of
the mutant.
Second, we used an antibody uptake protocol in which we
labeled the chimeric proteins using an anti-CD8 antibody at the
cell surface (Seaman, 2007) and studied internalization of the
CD8ED–sorLACD–WT and CD8ED–sorLACD–FTAF34A re-
porters in HeLa cells. In keeping with impaired retrograde traf-
ficking, we found that antibody bound to CD8ED–sorLACD–WT
was endocytosed and delivered to the trans-Golgi compartment
(TGN46-positive), whereas the CD8ED–sorLACD–FTAF34A
fusion protein accumulated in punctate structures (Fig. 4G).
A similar observation was made for the CD8ED–sorLACD–
FANSHY36A reporter (data not shown), confirming that the
aromatic motif is responsible for trans-Golgi network (TGN)
retrieval.
In addition to mediating retrograde transport back to the
Golgi, the TEN is also implicated in redirecting some receptor
molecules back to the plasma membrane via recycling vesicles. If
sorLA–FANSHY36A accumulates within the tubular compart-
ment as a result of deficient association with retromer, one could
speculate that over time (steady-state) that less soluble sorLA
would be released into the medium (as opposed to shedding of
newly synthesized receptors; see the pulse-chase experiment in
Fig. 4D). Despite almost identical expression of sorLA–WT and
sorLA–FANSHY36A in the stably transfected SH-SY5Y cells, we
consistently detected30% less shedding of themutant receptor
when compared with the WT receptor (p  0.0001) (Fig. 4H).
These data suggest that recycling of sorLA–FANSHY36A back
to the cell surface is impaired. From these studies, we elaborate on
a previously described model (Nielsen et al., 2007; Schmidt et al.,
2007) in which sorLA moves through the secretory pathway to
reach the cell surface. Our new studies suggest that, after inter-
nalization, sorLA is recycled back to the Golgi via the TEN—a
sorting step that requires binding of VPS26 of the retromer com-
plex to the FANSHY sequence in sorLA.
sorLA–FANSHY36A interacts with APP
We have demonstrated previously that sorLA can bind to and
retain APP in the Golgi compartment, thereby preventing pro-
cessing of APP via both amyloidogenic and non-amyloidogenic
pathways (Andersen et al., 2005; Schmidt et al., 2007). Because
retromer deficiency increases the amyloidogenic degradation of
APP (Small et al., 2005; Muhammad et al., 2008), we asked
whether the sorLA–FANSHY36A mutant might affect the sub-
cellular localization and sorting of APP.
We first performed double-IF microscopy for sorLA–
FANSHY36A and APP in the transfected SH-SY5Y cells. The
proteins exhibited a high degree of colocalization in the perinu-
clear region but notably also in the peripheral punctate structures
(data not shown). This observationwe corroborated using a PLA.
In brief, an immunostaining was performed inwhich the second-
ary antibodies were taggedwith oligonucleotides that can hybrid-
ize and be PCR amplified when antigens are within a distance of
40 nm. The resulting DNA strands were visualized by hybridiza-
tion of fluorescently labeled oligonucleotides. Staining with the
anti-sorLA and anti-APP antibodies generated a strong signal for
both sorLA–WT and sorLA–FANSHY36A (Fig. 5A). Notably,
although the signal for sorLA–WTandAPPwas visible in a region
close to the nucleus, it seemed that sorLA–FANSHY36A and
APP proximity was scattered throughout the cell, in line with the
dispersed distribution of the mutant receptor (cf. Fig. 3A).
In additional experiments, we used FLIM to analyze the direct
interaction of sorLA–WT and sorLA–FANSHY36A with APP.
In cells expressing APP alone, the lifetime of Alexa Fluor 488-
labeled APP in the absence of acceptor Alexa Fluor 543-labeled
sorLAwas 2163 127 ps (n 14). This lifetimewas shortened to
1979  182 ps (n  15; p  0.004) in the presence of labeled
sorLA. A similar reduction in the lifetime to 1982 116 ps (n
13; p  0.001) was found for the APP-conjugated donor in the
presence of sorLA–FANSHY36A, indicating that mutation
within the cytoplasmic domain of sorLA had little effect on the
complex formation between sorLA and APP (Fig. 5B).
We conclude that retromer is required for trafficking of sorLA
but not for formation of the sorLA:APP complex. Accordingly,
the sorLAmutant devoid in retromer binding is able to redistrib-
ute APP to a compartment with a similar morphology to the
TEN.
sorLA affects the trafficking of APP
Finally, we set out to investigate how sorLA–WT and sorLA–
FANSHY36A affect the vesicular transport of APP using time-
4
(Figure legend continued.) (streptavidinbeads) relative to the total expression level (input) in
SH-SY5Y cells shown by representative WB. C, Pulse-chase experiment after the maturation of
sorLA–WTand sorLA–FANSHY36A inSH-SY5Y cells. Their glycosylationpatterns are indicated
by white (immature) and black (mature) arrowheads. D, Pulse-chase experiment of secreted
sorLA ectodomains. E, Stability assay using pulse-chase technique. Proteins in C–E were visu-
alized by radiography. F, SH-SY5Y cells stably expressing sorLA–WT or sorLA–FANSHY36A
were stained for the receptor (in red) togetherwithmarkers of Golgi (ManII) or TGN (TGN46) (in
green). G, Anti-CD8 antibody uptake in HeLa cells transfected with CD8 ED–sorLA CD–WT or
CD8 ED–sorLA CD–FTAF34A. Endosome-to-Golgi retrieval was evaluated by colocalization
with TGN46. H, Secretion of sorLA extracellular domains at steady state determined by WB
analysis of 45 h conditioned medium (Secreted) from SH-SY5Y cells that express sorLA–WT or
sorLA–FANSHY36A (Cell).
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lapse imaging. Because previous studies had shown that
sorLA–WT significantly reduces the velocity of the exit of a
photo-activatable GFP–APP fusion protein from the perinuclear
region (Schmidt et al., 2007), we studied whether sorLA–
FANSHY36A possesses a similar ability to reduce the speed of
APP. We first transfected differentiated PC12 cells with APP–
EGFP and sorLA–RFP constructs to validate that sorLA impairs
APP trafficking. Not only did we observe a strong colocalization
of sorLA–WT andAPPwithin a subset of transport vesicles in the
perinuclear region (Fig. 5C), we also noticed a strongly reduced
velocity of vesicles containing both sorLA–RFP and APP–EGFP
compared with vesicle containing only APP–EGFP (data not
Figure 5. Binding of sorLA to retromer decreases APP transport and amyloidogenic processing.A, PLA using SH-SY5Y cells stably expressing sorLA–WT or sorLA–FANSHY36A and endogenous
levels of APP. The red signal indicates protein–protein interactions between sorLA andAPP.B, FLIM analysis of the interaction betweenAPP and sorLA–WTor sorLA–FANSHY36A in SH-SY5Y cells.
Shown are pseudocolored FLIM images (left) and lifetime histograms (right). C, PC12 cells were transfectedwith APP–EGFP and sorLA–WT–RFP and differentiated by treatmentwith 50 ng/ml NGF
to demonstrate colocalization between sorLA and APP in these cells. Vesicular movements were analyzed in PC12 cells, and representative kymographs from PC12 cells transfectedwith APP–EGFP
in the absence of exogenous sorLA or cotransfected with sorLA–WT or sorLA–FANSHY36A constructs are shown. Pausing vesicles are shown in blue, whereas vesicles moving anterograde and
retrograde are colored in green and red, respectively. D, Histograms showing the average mean speed for APP and the cumulative distance traveled by APP. Total number of vesicles analyzed per
conditionwere as follows: APP, 354 vesicles; sorLA–WT, 226 vesicles; sorLA–FANSHY36A, 287 vesicles. The vesicles were imaged over three experiments (n 3), and the data are represented as
mean SE. E, APP metabolism in SH-SY5Y cells analyzed by WB of lysates (Cell) and conditioned medium (Secreted) of nontransfected cells and cells expressing either sorLA–WT or sorLA–
FANSHY36A.Mature and immature fl-APP (indicated by arrowheads) in the lysatewas determined by antibody recognizing the C-terminal of full-length APP and secreted sAPPwas detected by
the WO2 antibody. F, Levels of sAPP and A in medium from SH-SY5Y cells determined by quantification of WB analysis or an A40-specific ELISA, respectively.
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shown). In a second round of experiments, we compared neurite
dynamics of APP–EGFP alone or after cotransfection with either
sorLA–WT or sorLA–FANSHY36A. In the absence of sorLA
expression, themajority of APP-containing vesicles weremoving
both retrogradely and anterogradely as shown by the kymograph
(Fig. 5C). On the contrary, coexpression of sorLA–WT retarded
transport of almost all APP-containing vesicles, reducing the cu-
mulative distance traveled from 30.8 to 8.3 m and the mean
speed of vesicles from0.15 to 0.03m/s (Fig. 5D). Remarkably, in
the presence of sorLA–FANSHY36A, movement of APP-
containing vesicles were identical to the APP inmock-transfected
cells.
These data suggest that sorLA only slows down APP traffick-
ing if the receptor resides in the Golgi apparatus.
The sorLA–FANSHY36Amutant does not protect against
APP processing
We next compared the impact of sorLA–WT and sorLA–
FANSHY36A on APP processing. To do so, we first compared
endogenous APP expression in parental SH-SY5Y with cell lines
transfected with either one of the two sorLA constructs. WB of
total cell lysates using an antibody against the C-terminal end of
APP revealed that levels of immature and mature APP were not
grossly affected by either sorLA–WT or sorLA–FANSHY36A
(Fig. 5E). However, when investigating shedding of soluble APP
in medium collected for 48 h, we found a 71.2  6.2% (p 
0.0001) reduction in secreted sAPP in sorLA–WT-expressing
cells. Interestingly, the sorLA–FANSHY36A mutant was signif-
icantly less potent than the WT protein in preventing sAPP
processing (54.0  7.0%; p  0.01) compared with nontrans-
fected cells (Fig. 5F).
Finally, we measured A secretion using ELISA to determine
the effect of the mutant receptor on the amyloidogenic process-
ing pathway. By comparing the medium from nontransfected
SH-SY5Y cells, we found a 30.8 3.2% reduction (p 0.0001) in
A production from cells that overexpress sorLA–WT. In con-
trast, sorLA–FANSHY36A did not offer any protection against
A production, because the level of A in the conditioned me-
dium was not significantly different from nontransfected cells
(Fig. 5F).
In conclusion, we have shown that sorLA is able to interact
with retromer via VPS26 and this binding is necessary to retrieve
to the Golgi complex. Aberrant sorLA trafficking by mutation in
the FANSHY motif or loss of retromer function leads to altered
APP processing and increased A production. Our findings sug-
gest a functional link between the impaired retromer expression
observed in some cases of sporadic AD and the increase in amy-
loid burden.
Discussion
The precise sorting of APP during endocytosis is of critical im-
portance for theADpathology becauseA generation (i.e., BACE
cleavage) occurs in the acidic environment of the endosome. Be-
sides endosomal sorting of APP, enlarged/dysfunctional endo-
somes have been implicated in AD progression, showing the
importance of delineating sorting mechanisms of endosomal
function (Nixon, 2005). This is supported by independent evi-
dence that revealed altered expression of various sorting recep-
tors and adaptors in AD (Small and Gandy, 2006).
In particular, defects in retromer-mediated transport have
been linked to AD development. Studies combining brain imag-
ing techniqueswithmicroarray analysis reported reduced expres-
sion of VPS35 and VPS26 in sporadic AD brains (Small et al.,
2005). In addition, it has been proposed that retromer deficiency
affects APP processing, thereby increasing A levels (Small et al.,
2005;Muhammad et al., 2008). Co-IP studies have indicated that
retromer and APP exist in a multiprotein complex, although a
direct interaction between APP and any of the retromer compo-
nents has not yet been identified (Vieira et al., 2010).
sorLA is member of a group of membrane proteins including
sortilin, CIMPR, and the iron transporter DMT1-II that undergo
retromer-dependent transport from the endosomal compart-
ments back to the Golgi. Recent studies have identified short
peptide motifs required for retromer association. These motifs
are highly hydrophobic and rich in aromatic amino acid residues,
e.g., the tripeptides FLV (sortilin), WLM (CIMPR), and YLL
(DMT1-II), respectively (Seaman, 2007; Tabuchi et al., 2010).
However, up to now, the nature of the sorLA signal involved in
retromer-dependent retrograde transport has not been eluci-
dated (Bonifacino and Hurley, 2008). Here we demonstrate that
retromer binds to an aromatic motif centered on F12 located in
the FANSHY motif in the sorLA cytoplasmic tail. This observa-
tion is in accordance with the general view that retromer binding
motifs contain aromatic residues. Interestingly, the binding of
retromer to sortilin was mapped to the larger region of the sorti-
lin cytoplasmic domain spanning the KKYVCGGRFLVHRYSV-
LQQHA sequence, containing the previously identified FLV
tripeptide (Canuel et al., 2008). Therefore, we speculate that the
separation between the two aromatic residues in this sequence (in
bold) exactly corresponds to the FANSHYmotif, suggesting that
these two aromatic residues may define a common recognition
motif for retromer within the family of mammalian VPS10
receptors.
Recognition of the FANSHYmotif by retromer likely is medi-
ated by the VPS26 subunit of the cargo-recognition VPS trimer.
This is the first demonstration of a role for VPS26 in cargo bind-
ing and is consistent with the structural studies of VPS26 that
revealed an arrestin-like conformation for theVPS26 protein and
predicted a possible cargo-binding activity by analogy with the
arrestin family of proteins (Shi et al., 2006; Collins et al., 2008).
Although studies in both yeast and mammalian cells have indi-
cated that VPS35 is responsible for the cargo-binding activity of
retromer (Nothwehr et al., 2000; Arighi et al., 2004), our data
suggest that this is not the case with respect to sorLA binding.
The role of the FANSHY motif in the sorLA cytoplasmic tail
was investigated by mutagenesis. We found that sorLA–
FANSHY36A exhibits an altered cellular distribution to struc-
tures that were similar to the localization observed in cells lacking
the retromer complex (Fig. 3D). In conclusion, mutating sorLA
in the FANSHY motif or removing the retromer complex both
lead to accumulation of the receptor in vesicular structures. The
localization of sorLA–FANSHY36A was clearly changed to a
more vesicular structure that was positive for neither markers of
TGN, late endosomes, nor lysosomes (data not shown). How-
ever, the observed pattern was similar to the localization of the
retromer subunits VPS26 (Arighi et al., 2004), SNX1 (Carlton et
al., 2004), and SNX2 (Carlton et al., 2005), which have been
reported as tubules of the endosome, i.e., the TEN (Bonifacino
and Rojas, 2006). A caveat to our study is that no specificmarkers
for the TENare yet known and that identification of the compart-
ment solely relies on its morphological appearance. Obviously,
this problem represents a significant challenge for future studies.
Therefore, we hypothesize that sorLA–FANSHY accumulates
in the TEN, whereas sorLA–WTmolecules can continuously un-
dergo retromer-dependent retrograde transport back to the
Golgi from the TEN (step 5; Fig. 6). Thus, the WT receptor can
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also be recycled to the plasma membrane to populate the cell
surface more extensively than sorLA–FANSHY36A as well as
undergo secretion after cleavage, a process that also takes place at
the cell surface (Fig. 6). Furthermore, our data suggest amodel in
which sorLA travels independently of retromer activity through
the secretory pathway to the cell surface (steps 1–3). Also, endo-
cytosis of sorLA by clathrin-coated pits into early/sorting endo-
somes (step 4) occurs independently of the retromer complex in
line with previous findings that suggested that clathrin and ret-
romer function in consecutive retrograde sorting steps (Popoff et
al., 2007). This model is supported by a recent study describing a
sorLA–F12N14Y173Asmutant, which did not change the rate of
internalization (Nielsen et al., 2007).
sorLA–WT is primarily localized within the Golgi and TGN,
in which it functions as a retention factor for APP (Schmidt et al.,
2007), resulting in less APP available for processing (Andersen et
al., 2005; Offe et al., 2006). Therefore, a lack of sorLA retrieval
from endosomes/TEN to the Golgi/TGN in the absence of retro-
mer activity would lead to reduced sorLA binding to APP in the
post-Golgi secretory pathway. Similarly, disrupting the interac-
tion between sorLA and retromer by mutation of the FANSHY
motif would also decrease the amount of sorLA in Golgi/TGN.
Figure 6. Model of the sorLA intracellular sorting pathways. A, The amino acid sequence of sorLA including known binding sites for the specific cytosolic adaptor proteins retromer (FANSHY),
PACS1/AP-2 (acidic sequence), and GGA (MVIA).B, APP processing pathways. In the amyloidogenic pathway (red; to the left), APP is cleaved by-secretase to generate sAPP and subsequent by
-secretase to produce the A peptide. In the non-amyloidogenic pathway (green; to the right),-secretase cleaves within the A sequence to generate sAPP but inhibits amyloid production.
C, Schematic roadmap of themajor transport pathways ofWT and retromer-deficient binding sorLA in cells. Newly synthesized sorLA from ER traverses the Golgi en route to the plasmamembrane
in the secretory pathway independent of the FANSHYmotif (steps 1–3). Both sorLA–WTand sorLA–FANSHY36Aare internalized from the cell surface (step 4) into the early endosome inwhich the
receptors are sorted into distinct tubules of TEN (Andersen et al., 2005; Nielsen et al., 2007; Schmidt et al., 2007). Several pathways exist for exiting the TEN either into recycling endosomes going
back to the cell surface or retrograde transport to the Golgi compartment depending on the different cytoplasmic coats surrounding individual tubules. We propose that the sorLA–FANSHY36A
mutant accumulates within SNX-coated tubules, being unable to associate with the cargo-specific VPS subunit of the retromer. In contrast, sorLA–WT is efficiently sorted back to the Golgi (step 5),
leading to a higher steady-state level of sorting receptor (compared with the FANSHY36A mutant) that also leads to higher levels at the cell surface (steps 6 and 7). APP is primarily localized in
intracellular compartments, in which the interactionwith sorLA–WT retains APP in the perinuclear compartments, leading to less shedding of sAPP from the cell surface, and hinders entry to the
amyloidogenic processing in the late endosomal pathway. sorLA–FANSHY36A also in part inhibits APP degradation to sAPPbecause of the initial localization at the plasmamembrane, but there
is very little receptor available to inhibit the amyloidogenic sorting into the late endosomes because this variant sorts into the TEN.
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Hence, either the FANSHYmutation or the loss of retromer func-
tion will lead to a reduction of the Golgi/TGN localized sorLA
and, consequently, increased APP trafficking to endosomal com-
partments. Thismislocalization causes enhanced APP processing
and increased A levels. We believe that the removal of a func-
tional interaction between sorLA and retromer bymutagenesis of
the binding site represents an excellent model to study the im-
portance of retromer-mediated APP transport compared with
the retromer-deficient situation (Muhammad et al., 2008). The
results of such studies may, however, be confounded by side ef-
fects from retromer acting on third-party proteins also involved
in APP processing, e.g., BACE (He et al., 2005).
It is known that APP can be processed at the cell surface by
-secretase, whereas uncleaved molecules can internalize and
undergo cleavage by -secretase in the endocytic compartments.
In cells that express sorLA–FANSHY36A, we observed an in-
crease in both sAPP and A levels, suggesting less protective
receptor activity in the Golgi/TGN (loss of function) (Fig. 5).
However, the increased expression of sorLA–FANSHY36A
within the endosomal system (gain of function) could alterna-
tively associate with APP to reduce the exit of APP from the TEN,
thereby enhancing the possibility of amyloidogenic cleavage
within the acidic endosomal compartment. Also, a decrease of
non-amyloidogenic cleavage at the cell surface could result from
less APP trafficking from the TEN via recycling endosomes back
to the plasmamembrane. Currently, we are unable to distinguish
between these two scenarios, and, in reality, both mechanisms
could add to the observed differences. However, because sorLA–
FANSHY36A is also not able to lower the non-amyloidogenic
processing, we believe that the reduced sorLA levels within the
early compartments (loss of function) plays themajor role in our
model.
In conclusion, the present study identifies amino acid residues
in the cytoplasmic domain of sorLA essential for the interaction
with components of the retromer complex.We show that disrup-
tion of the FANSHYmotif within sorLA leads to accumulation of
the receptor in a distinct intracellullar compartment, most likely
retromer-associated tubules of the TEN, which leads to increased
A production as seen in AD patients suffering from low expres-
sion levels of either sorLA or retromer.
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